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In the presence of plasma transglutaminase (factor
Xllla) fibrin first undergoes intermolecular covalent
cross-linking between its 'Y chains to create 'Y dimers
followed by slower cross-linking among its a chains to
form a polymers. Progressive cross-linking of 'Y chain
dimers occurs at the slowest rate, resulting in 'Y trimers
and 'Y tetramers ("-y multimers"). Most studies indicate
that cross-linked fibrin clots become resistant to fibrinolysis, but the basis for this event is not clear. In this
study, we explored the role of 'Y chain multimerization
compared with a polymerization as causal factors in
time-dependent development of resistance to fibrinolysis. Fibrin clots prepared from native (intact) fibrinogen
were incubated for up to 120 h at near physiological
ionic strength and a factor Xllla level approximating
that in plasma. These clots were lysed by plasmin at
rates that were inversely proportional to the level of 'Y
multimers, which increased progressively with the time
of incubation. In contrast, fibrin cross-linked at high
ionic strength (a condition under which only 'Y dimers
and a polymers form) or fibrin formed in the absence of
factor XIII showed no time-dependent decrease in lysis
rates. Fibrin cross-linked for a fixed time period with
increasing amounts of factor Xllla contained 'Y multimer
levels that were proportional to the factor Xllla concentration and lysed at rates that were inversely proportional to the 'Y multimer level. Furthermore, cross-linked
fibrin formed from fibrinogen fraction 1-9, which has
limited potential for a polymerization, showed the same
reduction in the lysis rate as native cross-linked fibrin.
These findings indicate that development of resistance
to fibrinolysis of cross-linked fibrin is not measurably
dependent upon 'Y dimer or a polymer formation but
develops solely as a function of 'Y multimerization.

Following thrombin-catalyzed conversion of fibrinogen to fibrin, polymer assembly commences with noncovalent intermolecular interactions between the D domains and the E domains
of neighboring molecules (1-6), resulting in double-stranded
fibrils composed of a half-staggered overlapping array of molecules (7-13). These fibrils subsequently associate laterally,
forming thick fibers that constitute the major structural elements of the branched fibrin matrix (10, 14--20).

* This work was supported by NHLBI Grant HL-47000. The results of
this study were presented at the XIV Congress of the International
Society on Thrombosis and Hemostasis in July, 1993 (Siebenlist, K. R. ,
and Mosesson, M. W. (1993) Thromb . Haemostasis 69, 543). The costs of
publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
11 To whom correspondence should be addressed: Sinai Samaritan
Medical Center, Winter Research Bldg., 836 North 12th St., Milwaukee,
WI 53233.

In the presence of plasma transglutaminase (factor XIIIa)
and Ca 2•, fibrin undergoes intermolecular covalent cross-linking by formation of e-amino( y-glutamyl) lysine isopeptide bonds
(21, 22). Cross-linking of y chains within fibrils occurs in properly aligned chains between lysine at position 406 of one y
chain and a glutamine at position 398 or 399 of another (23-26)
to form y dimers (27, 28) (only one of the two possible bonds is
necessary to form covalent y chain dimers (20)). Intermolecular
cross-linking between a chains creates oligomers and larger a
chain polymers and occurs more slowly than y dimerization (28,
29). A minor amount of cross-linking also occurs between a
chains and 'Y chains (20, 30). It has recently been established
that higher order forms of cross-linked y chains, "y multimers"
(i.e. y trimers, y tetramers) also occur (20, 30, 31), most likely
through interfibril bond formation. Under conditions approximating those found in vivo, 'Y multimers form over a period of
hours to days, an order of magnitude more slowly than a polymers, which form within minutes to hours (31); 'Y multimers
also can form at shorter time intervals by raising the level of
factor Xllla (31).
Plasmin digestion of cross-linked fibrin in the presence of
Ca 2• gives rise to a series of high molecular weight E-containing
cross-linked intermediate fragments (e.g. DY,1 D3 ·E) that are
larger than 'Y chain cross-linked D dimers (32-39). At more
advanced stages of proteolysis, E-containing fragments are consumed, resulting in free E domains and cross-linked D multimers (D-D, D3 , D4 ), with D dimers predominating (20, 40--42). D
multimers persist in digests containing Ca 2• since Ca 2 • confers
resistance to plasmin cleavage in the carboxyl-terminal region
of the 'Y chain (40-43), resulting in retention of the 'Y chain
segment containing the covalent cross-link.
Because of its great potential physiological significance, the
susceptibility of cross-linked fibrin clots to lysis by plasmin has
been extensively studied, yet it remains a controversial and
incompletely understood subject. Many studies indicate that
the lysis rate of cross-linked fibrin is lower than that of noncross-linked fibrin clots (44--53), an effect that has been attributed by several investigators to formation of high molecular
weight a polymers (49, 52, 53). In other studies, no differences
between the lysis rates of cross-linked and noncross-linked fibrin were observed (29, 33, 54-56), and on this basis it was
concluded that lytic rates are not affected by either a or y chain
cross-linking (55). A unified explanation for these discrepant
observations and conclusions regarding cross-linking and lysis
has still not been found.
1 The abbreviations used are: DY, an intermediate D dimer-containing fragment with one D domain retaining a covalently linked E domain
(i.e. fragment D-DE); D3 ·E, an intermediate E-containing fragment having three D domains (i.e. a D trimer), one of which retains a covalently
linked E domain (this fragment is equivalent in D and E composition
and size to fragment DX, an intermediate D dimer-containing fragment
consisting of a fragment X molecule linked covalently to a D domain
(32)); D-D, D dimer; D3 , D trimer; D4 , D tetramer.
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Resistance to Fibrinolysis
Resistance to fibrinolysis develops in in vivo thrombi over a
period of several days (57-61) or even months (62), although
the reasons for this have not been adequately defined. The
realization that the levels of -y multirners in fibrin increase
slowly and progressively with time, in apparent temporal relationship to the development ofin vivo resistance to fibrinolysis,
prompted us to explore the role of -y chain multimerization in
this process. Particular attention was paid to comparison of a
chain polymerization and -y chain multimerization in order to
distinguish their individual effects on plasmin lysis rates.
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EXPERIMENTAL PROCEDURES
Tris, glycine, urea, and dithiothreitol were purchased from Aldrich.
Coomassie Brilliant Blue R-250 was obtained from Sigma. Aprotinin
(Trasylol) was obtained from Mobay Chemical Corp. , New York, NY, a nd
DE-52 cellulose was from Wh atman. Human a thrombin was a generous gift from Dr. John Fenton II. Other chemicals were the highest
purity available from commercial sources.
Human fibrinogen was isolated from pooled citrated plasma by glycine precipitation (63) and further fractionated into fractions I-2 and I-9
as described by Mosesson and Sherry (64). Fraction I-9 fibrinogen had
very low levels of factor XIII activity (0-2 units/mg fibrinogen ). Peak 1
fibrinogen, consisting mainly of native molecules (>75% intact Ao.
chains) and free of factor XIII (65), was prepared from fraction I-2
fib,;_nogen by chromatography on DE-52 (66, 67). Clottability of the
fibrinogen fractions was greater than 98%. Fibrinogen concentrations
were determined spectrophotometrically at 280 nm using an absorbance coefficient (A :~m) of 15.1 (65). Plasminogen was isolated from
pooled citrated human plasma by affinity chromatography on lysineSepharose (68), activated to plasmin by incubation with streptokinase
(1:800 molar ratio) for 20 h at room temperature (69), and assayed
colorometrically using Kabi S-2251 (Helena Laboratories, Beaumont,
TX) as substrate. Purified factor XIII was prepared from citrated human plasma (70), a nd its activity was determined as described by Loewy
et al. (71). These preparations had a specific activity of 1500-2100
units/mg. Plasma factor XIII activity is 50-120 units/ml.
SDS-polyacrylamide gel electrophoresis was performed as described
by Weber and Osborn (72) for tube gels (5 mm diameter) or on 1.5-mm
slab gels using the method of Laemmli (73). Five percent polyacrylarnide gels were used for nonreduced samples and 7.5 or 9% gels were used
for completely reduced sam ples. Gels were stai ned with 0.5% Coomassie
Brilliant Blue R-250 in methanol/water/acetic acid (5:5:2) for 1 h at
room temperature and destained in methanol/water/acetic acid (5:5:2)
with continuous shaking.
Standard clotting conditions consisted of fibrinogen (fraction I-2 or
I-9, 3 mg/ml) in 50 mM Tris, 100 mM NaCl, 10 mM CaC1 2, 4 mM dithiothreitol, 10 KIU/ml Trasylol, pH 7.4, buffer (I= 0.17). Cross-linking
mixtures were supplemented to physiological levels of factor XIII (50
units/m l, final). Clotting and cross-linking were initiated by adding
t hrombin (0.25 units/ml, final ). The mixtw·es were incubated at room
temperature for up to 5 days. Cross-linked fibrin clots containing varying concentrations of factor XIII (0-100 units/ml) were also prepared at
room temperature for 24 h. Clots cross-linked at high ionic strength
were formed in 50 mM Tris, 500 mM NaCl, 10 mM CaC1 2, 4 mM dithiothreitol , 10 KIU/ml Trasylol, pH 7.4, buffer (I= 0.57). Under each of the
cross-linking conditions used, monomeric -y chains were consumed
within 30 min a nd monomeric 0t. chains were consumed within 10 h.
Cross-linked fibrin clots were formed in citrated fresh single donor
human plasma by either adding Trasylol (10 KIU/ml) and then recalcifying by adding CaC12 to a 10 mM excess over the citrate concentration
or by adding thrombin (0.25 units/ml) and CaCl 2 at a 10 mM excess over
citrate. Noncross-linked clots were formed by adding EDTA (2 mM),
Trasylol (10 KIU/ml), a nd thrombin (0.25 units/ml, final ) to plasma. The
mixtures were incubated at room temperature for up to 120 h.
Plasm in digestion of fibrin was carried out on clots that had been
wound on glass rods and incubated for 1 h in 50 mM Tris, 10 mMCaC12,
pH 8.6, buffer contai ning 5 mM N-ethylmaleimide to inactivate factor
XIIIa (complete loss of activity occurs within 30 min). (Addition of
N-ethylmaleimide under standa rd clotting conditions prior to factor
XIII activation completely inhibits cross-linking without affecting clot
formation .) The N-ethylmaleimide-treated clot was then washed 3
times with 50 mM Tris, 10 mM CaC1 2, pH 8.6, buffer and digested in this
buffer with plasmin (0.2 caseinolytic units/ml, final). At selected intervals, the digestion mixture was briefly centrifuged to pelJet-insoluble
materia l, and absorbance readings at 280 nm were made on the clear
supernatant so lution . The rate of plasmin digestion , expressed as per-

120

60

180

240

300

360

Plasmin Lysis Time

o,"-o3E - - D ~
0-DE/
0-DD E -

aChain {
Fragments

15'

30'

60'

120'

240'

360'

Frc. 1. Fibrin clots were formed from factor XIII-free fibrinogen with added factor XIII (50 units/ml) under near physiological buffer conditions (I = 0.17) and lysed by the addition of
plasmin (0.2 caseinolytic units/ml). At the times indicated on the
abscissa, insoluble material was removed, and the clear supernatant
was used to determine the amount of clot solubilized and composition of
the released fragments. SDS-polyacrylamde gels of the released soluble
fragments at various sampling times are inset along the bottom of the
curve.

cent of total protein released/min (%/min), was calculated from absorbance readings taken during the linear phase of lysis. Under these
digestion conditions, no E-containing intermediates remained at the
end of a 24-h digestion period, and no significant changes in the composition of digest components were observed at more extended digestion
periods.
-y chain multimers (i.e. -y trimers and -y tetramers) in cross-linked
clots were quantified as described previously (3 1) by determining the D
trimer and D tetramer content in a terminal nonreduced plasmin digest. The D fragment-containing composition (D tetramer, D trimer, D
dimer, and D monomer) was determined by densitometric gel scanning
using a Gilford Response Spectrophotometer equipped with an Autoradiogram Scanning kit. The tube gels used to separate the D fragments
were prepared for analysis by photographing t he gels, printing the
negative on a sheet of Kodak type 4489 film, and then scanning the
positive fi lm print. This method of scanning gels gave linear cw-ves for
peak area versus protein load in the range of0-500 µg of protein applied
to the gel. The results reported are th e averages of three to six separate
experiments.
RESULTS

A typical lysis curve obtained from cross-linked fibrin clots
treated with plasmin is presented in Fig. 1. As can be noted
from this plot, release of soluble fragments was linear for the
first 240 min oflysis, and in most cases release was linear over
the entire 360 min of observation. The lysis rate was determined from the slope of the linear region of the curves (%/min).
At the earliest sampling time (15 min), only a chain fragments
h ad been released. Samples taken subsequently contained all
of the expected high molecular weight end products (D4 , D3 ,
D-D , D, and E ) along with intermediate E-containing fragments D3 ·E and DY. The amount ofD tetramer and D trimer in
these samples was constant throughout the digestion at 2.8 ±
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Fm. 2. Fibrin clots were Conned without added factor XIII

from factor XIII-free fibrinogen under near physiological buffer
conditions (I • 0.17) (panel A) or with added factor XIII (50
units/ml) at near physiological ionic strength (panel B) or at
high ionic strength <I• 0.57) with added factor XIII (panel C). At
the times indicated on the abscissa the plasmin lysis rates of these clots
(•) and the -y trimer and -y tetramer levels in digests (0) were determined. The zero time point is the lysis rate of an uncross-linked fibrin
clot. Results shown are the means from six separate experiments.

0.2% D tetramer and 3.2 :t 0.4% D trimer. Intermediate fragments D3·E and DY were eventually consumed after clot lysis
was completed.
When aliquots of factor XIII-free peak 1 fibrinogen were clotted under near physiological buffer conditions for up to 120 h
and then lysed with plasmin, no significant change in the lysis
rate of noncross-linked clots occurred during the incubation
period (Fig. 2A) (mean lysis rate, 0.27 :t 0.01%/min). Incubation
of peak 1 fibrin under the same buffer conditions in the presence of physiological concentrations offactor XIII (50 units/ml)
yielded cross-linked clots that lysed at decreasing rates as the
time of incubation increased (Fig. 2B). Clots that had been
cross-linked for 12 h before plasmin addition lysed at a rate of
0.23%/min, whereas clots incubated for 120 h lysed at a reduced
rate of 0.16%/min. The 'Y trimer and 'Y tetramer content of the
cross-linked clots, as assessed by determination of the D trimer
and D tetramer content in terminal plasmin digests, increased
progressively with cross-linking time and amounted to 6.8% by
120 h (Fig. 2B ). By contrast, cross-linked clots formed at high
ionic strength (conditions under which complete 'Y dimer and a
polymer formation occur but 'Y trimers and 'Y tetramers do not
form (31)) were lysed by plasmin at the same rates as noncrosslinked clots over the entire period of cross-linking (mean lysis
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Fm. 3. Fibrin clots were formed from factor ml-free fibrino•
gen at concentrations of factor XI1I varying from 0 to 100
units/ml under near physiological buffer conditions (closed symbols) or at high ionic strength (open symbols). After incubation for
24 h, the plasmin lysis rates (squares) and the -y trimer and -y tetramer
levels (circles) in digests of these clots were determined. The results
shown are the means from four separate experiments.

rate, 0.27 :t 0.1%/min) (Fig. 2C).
Plasmin lysis rates were also measured on clots formed for a
fixed time period (24 h) at differing concentrations of factor
XIII. At physiological ionic strength, the plasmin lysis rate
decreased and the 'Y multimer content increased as a function of
increasing factor XIII concentration (Fig. 3). For example, at 5
units/ml of factor XIII, the lysis rate was 0.26%/min and the
clot contained 1.4% 'Y multimers, whereas at a factor XIII concentration of 100 units/ml the lysis rate was 0.16%/min at a 'Y
multimer content of 7.2%. Under high ionic strength conditions, where 'Y multimers do not form, no change in lysis rate
was observed, and the mean lysis rate was the same as that for
noncross-linked clots (0.27 :t 0.01 %/min).
'lb distinguish the effects of a polymer formation from those
of 'Y trimers and 'Y tetramers on plasmin lysis rates, these
experiments were repeated using fibrinogen fraction 1-9, which
is a plasma fibrinogen catabolite lacking carboxyl-terminal regions of the Aa chain (74) and thus has limited potential for
forming a polymers (75). When plasmin lysis rates were measured on cross-linked clots formed from fraction 1-9 fibrinogen,
the rates decreased with increasing time of incubation (Fig. 4)
as an inverse function of the 'Y multimer content. The plasmin
lysis rates and the levels of 'Y multimers observed with crosslinked 1-9 fibrin over time did not differ significantly from those
observed with cross-linked peak 1 fibrin (cf Fig. 2B and Fig. 4).
At high ionic strength, no 'Y multimers formed and there was no
change in the lysis rate with time (mean lysis rate, 0.27 :t
0.01%/min). As expected, fraction I-9 fibrinogen that had been
clotted in the presence of increasing concentrations of factor
XIII for a fixed incubation period, lysed at rates that were
nearly identical to those obtained with peak 1 fibrinogen (Fig.
5). Lysis of clots formed at high ionic strength showed no
change in lysis rates.
The effect of 'Y trimer and 'Y tetramer formation on plasmin
lysis rates of clots formed from plasma was also examined.
Noncross-linked plasma clots Jysed at the same rate as noncross-linked clots prepared in the purified system. The lysis
rates of cross-linked plasma clots decreased from this initial
value, and the content of 'Y trimers and 'Y tetramers increased in
direct relation to the time of cross-linking (data not shown).
DISCUSSION

The data presented here demonstrate that cross-linked fibrin
clots develop resistance to plasmin lysis as a function of 'Y
multimerization, namely 'Y trimer and 'Y tetramer formation.
There appears to be no directly measurable relationship between development of resistance to clot lysis and the degree of
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plasmjn lysis rates (squares) and the -y trimer and -y tetramer levels
(circles) in digests of these clots were determined. The results shown
are the means from four separate experiments.

a chain polymerization. This contention is supported by two
lines of evidence. First, native fibrinogen developed resistance
to lysis only under conditions where y multimers formed,
namely at near-physiological ionic strength. When cross-linked
clots were prepared at high ionic strength, only y dimerization
and a polymerization occurred, and these clots lysed at the
same rate as noncross-linked clots. Second, the lysis rates of
cross-linked clots prepared from fraction I-9 fibrinogen, which
h as limited potential for a chain polymerization, were not significantly different from those obtained from native crosslinked fibrin, in which a polymerization occurred.
Plasmic digestion of cross-linked fibrin leads to the early
release of cross-link-containing a chain segments from core
structures by proteolytic cleavage at residues that are aminoterminal to the glutamine and lysine resides involved in a
chain cross-linking (36, 75-78) (cf. Fig. 1). Thus, such crosslinked a chain structures do not contribute to the structure of
intermediate or terminal core fragments containing D and/or E
domains, making it unlikely that a polymers, p er se, play a
significant role in delaying the release of core fragments from
the cross-linked fibrin matrix.
Clot solubilization occurs by release of core molecular fragments containing the D and/or E domains that comprise the
major interacting structural elements of the assembled clot and
results largely from intramolecular cleavages between the D
and E domains. Consideration of the structural placement of
covalent cross-links between the y chains and the a chains in
fibrin and the sequence of proteolytic attack on the matrix
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Soluble Fragments

Fie. 6. Schematic diagram illustrating the sequence of events
leading to the dissolution of cross-linked fibrin. Double-stranded
fibrin fibrils are depicted as consisting of fibrin molecules (D domains,
large ovals; E domains, small ovals ) arranged in a half-staggered array
ofnoncovalent end-to-middle D-E pa irings (dotted lines). -y chrun crosslinks are shown as single or double solid lines bridging between -y chains
of neighboring D domains. -y chain bridging arrangements resulting in
-y dimers, -y trimers, and -y tetramers, are indkated by shadowed D
domains. a polymer structures are represented by a network of wavy
lines (a chains) connected by solid lines (cross-links). During the injtial
phase of plasmin lysis, cross-linked a chain fragments are released,
leaving the bulk of the covalent structure of the fibrin matrix intact. In
later phases oflysis, plasmin cleaves a mjnimum of three peptide bonds
in the coiled coil region of each fibrin molecule, causing separation of D
and E domains. The boxed numbers indicate the number of DIE scissions that are required to release solubl e cross-linked D-contruning
fragments.

suggests a logical explanation for why y trimer and y tetramer
formation is the singular event in the fibrin cross-linking process that accounts for development ofresistance to plasmin lysis
(Fig. 6). Formation of y dimers by cross-linking at specific glutamine and lysine y chain sites in the COOR-terminal region
(23-26) occurs within or along polymerized two-stranded fibrils
(27). Cross-linking within fibrils results in y dimer formation
between two neighboring D domains. These cross-linked core
fragments are released as a unit (i.e. D dimer) when internal
cleavages occur that separate them from their E domains. In
contrast, given the fact that there is only one lysine donor site
per y chain, y trimers and y tetramers must arise by bond
formation between D domains of neighboring fibrils comprising
the matrix or, in the case of y trimers, may also occur at trimolecular branch points (20, 31), a relatively uncommon event.
Dissolution of fibrin matrices containing y trimers or y tetra-

28418

Resistance to Fibrinolysis

mers requires the cleavage of a greater number of interdomainal peptide bonds for release of cross-linked core fragments
such as D trimers and D tetramers from the clot matrix as
solubilized fibrin degradation products. The requirement for a
greater number of cleavages for cross-linked fragment release
can account for the delay in solubilization of the matrix by one
of two mechanisms. 1) It could slow the overall solubilization
rate of the clot, or 2) it could slow the release and solubilization
only of fibers containing such cross-linked core structures. In
the first case, the ratio of D dimers to D trimers and D tetramers in the digest would be constant throughout digestion,
whereas in the second instance, the proportion ofD trimers and
D tetramers in the digest would increase progressively during
the course of digestion. The first scenario appears more likely
since after the initial release of cross-linked a chain fragments,
the ratio of D dimers to D trimers and D tetramers remains
constant over the entire course of clot dissolution (cf Fig. 1).
An explanation for the discrepant observations and interpretations regarding the effect of fibrin cross-linking on plasmin
lysis can now be offered. Reports on fibrin clot lysis in which the
lysis rate of cross-linked fibrin was decreased compared with
noncross-linked fibrin (44-53) most likely involved fibrin clots
containing a sufficient proportion of 'Y chain multimers to
render them resistant to fibrinolysis. Generally, these studies
utilized clots that had been incubated for extended periods of
time and/or had been cross-linked at high concentrations of
factor XIII. In contrast, those studies showing no differences
between the lysis rates of cross-linked and noncross-linked fibrin (29, 33, 54-56) probably reflect the lysis of clots that contained 'Y dimers, and possibly a polymers as well, but which
were formed under conditions that were insufficient to produce
the degree of 'Y multimerization that is necessary to retard
fibrinolysis.
Extensive 'Y trimer and 1' tetramer formation as a function of
time of incubation has been demonstrated in plasma clots (31).
1' trimers and 1' tetramers have also been found in clots formed
in vivo. y chain multimers increased progressively in femoral
artery thrombi formed in dogs when left in the circulation for
increasing periods oftime, 2 and they were found in the wall of
an aortic aneurysm that had existed in vivo for several
months. 3 The proportion of 1' trimers and 1' tetramers found in
the aneurysmal wall fibrin was directly related to the sampling
site; the lumenal (younger) portion of the wall contained fewer
'Y multimers than older more exterior portions of the wall. The
exact relationship between 1' trimers and 1' tetramers on the
plasmin lysis rates of these in vivo clots has yet to be determined, but it is known that resistance to lysis of fibrin in
aneurysmal walls increases as a function of its distance from
the lumen (62).
Other factors contributing to in vivo resistance to fibrinolysis
include cross-linking of a 2-plasmin inhibitor to the fibrin clot, a
process that decreases the rate of fibrinolysis (79-83), especially during initial phases of lysis induced by plasminogen
activators. Clot retraction by itself increases clot resistance to
lysis by condensing the a 2-plasmin inhibitors that are crosslinked to fibrin (84). In addition, decreased plasminogen binding to cross-linked fibrin may affect fibrinolysis induced by
plasminogen activators (82, 85). Finally, fibroblast deposition of
collagen during resolution of thrombi may contribute to progressive development of resistance to lysis in vivo (86). The
susceptibility of an in vivo thrombus to plasmin lysis is no
doubt modulated by a combination of these factors, not the
least of which is 1' multimerization.
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